MASTER DAPT AMI
Overview
Investigator-initiated
global randomized study
global randomized study
4,579 patients,
140 hospital worldwide, 30 countries
140 hospital worldwide, 30 countries
All-comers trial in
HBR patients after PCI
HBR patients after PCI
Abbreviated vs prolonged
DAPT in patients treated with
the Ultimaster™and Ultimaster™ Tansei™ DES
DAPT in patients
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
Study Design
MASTER DAPT Trial
Primary Endpoint
- Net adverse clinical events (NACE) defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
- Major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
- Major or clinically relevant non-major bleeding (MCB), defined as BARC 2, 3 or 5 bleeding.
Result
NACE
All cause death, Myocardial infection, Stroke and BARC 3 or 5 Bleeding
Prior MI HR 0.83, 95% CI 0.61-1.12; p=0.22
No prior MI HR HR 1.03, 95% CI 0.77-1.38; p=0.85
Pinteraction=0.30
MACCE
All cause death, Myocardial infection, Stroke
Prior MI HR 0.86, 95% CI 0.62-1.19; p=0.236
No prior MI HR 1.13, 95% CI 0.80-1.59; p=0.48
Pinteraction=0.25
Major or clinically relevant non-major bleeding
BARC 2,3 or 5 bleeding
Prior MI HR 0.65, 95% CI 0.46-1.91; p=0.01
No prior MI HR 0.71, 95% CI 0.54-0.92; p=0.401
Pinteraction=0.72
MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe.
Related Clinical Evidences
